Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

miR-15a and 16-1 are downregulated in CD4(+) T cells of multiple sclerosis relapsing patients.
Natalizumab to fingolimod washout in patients at risk of PML: When good intentions yield bad outcomes.
Behavioral interventions in multiple sclerosis: a biopsychosocial perspective.
Tangier's disease: An uncommon cause of facial weakness and non-length dependent demyelinating neuropathy.
Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.
Revisiting brain atrophy and its relationship to disability in multiple sclerosis.
Fine-tuning the central nervous system: microglial modelling of cells and synapses.
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
MAIT cells in autoimmunity.
Medication withdrawal in relapsing-remitting multiple sclerosis: why not?
"Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis.
Accentia Biopharmaceuticals Announces that Revimmune Autoimmune Disease Therapy is Featured in Peer-review Journal
Catheter venography and endovascular treatment of chronic cerebrospinal venous insufficiency.
Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain.
Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions.
Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis.
Autophagic myelin destruction by schwann cells during wallerian degeneration and segmental demyelination.
Brain Region-specific Alterations in the Gene Expression of Cytokines, Immune Cell Markers and Cholinergic System Components During Peripheral Endotoxin-induced Inflammation.
HLA-A(∗)02, gender and tobacco smoking, but not multiple sclerosis, affects the IgG antibody response against human herpesvirus 6.
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties.
The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I).
Is multiple sclerosis an autoimmune disease?
Premorbid physical activity predicts disability progression in relapsing-remitting multiple sclerosis.
Th17 Cells in Neuromyelitis Optica Spectrum Disorder: A review.

Pages